Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Veru Inc. (NASDAQ: VERU) announced that updated Phase 1b/2 clinical data for sabizabulin (VERU-111) in men with metastatic castration resistant prostate cancer will be presented at the ESMO Congress 2021, from September 16-21, 2021. Sabizabulin targets unique microtubule binding sites and aims to disrupt androgen receptor transport. The presentation takes place on September 19, 2021, by Dr. Mark C. Markowski. Meanwhile, the ongoing Phase 3 VERACITY trial evaluates sabizabulin against alternative treatments in chemotherapy-naïve patients.
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company, announced its participation in several upcoming healthcare investor conferences. Key dates include the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23, and the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. Presentations will be available online and archived for 90 days. Veru focuses on developing innovative treatments for prostate and breast cancer.
Veru Inc. (NASDAQ: VERU) reported a robust Q3 FY21, with net revenues soaring by 71% to $18M and gross profit jumping 113% to $14M, both achieving record highs. Year-to-date revenues reached $46M, marking a 48% increase. The company is advancing its oncology pipeline, with multiple clinical trials for prostate and breast cancers underway. Cash and equivalents stood at $123M, ensuring investment capacity for ongoing programs. Veru also initiated a Phase 3 COVID-19 trial, bolstering its therapeutic portfolio as the pandemic persists.
Veru Inc. (NASDAQ: VERU) announced it will report its fiscal 2021 third-quarter financial results on August 12, 2021, before market opening. A conference call is scheduled for the same day at 8 a.m. ET to discuss performance and address questions. Veru is focused on oncology, developing treatments for prostate and breast cancer. Current clinical trials include sabizabulin targeting resistant prostate cancer and enobosarm for metastatic breast cancer. The company also has a Sexual Health Business, featuring the FDA-approved FC2 Female Condom.
Veru Inc. (NASDAQ: VERU) announced updated clinical results for sabizabulin (VERU-111) in a Phase 1b/2 trial targeting metastatic castration-resistant prostate cancer. The study results, well received for their potential effectiveness, will be presented at the European Association of Urology 36th Annual Congress from July 8-12, 2021. The company plans to advance the drug to a Phase 3 trial, named VERACITY, aiming to address a significant unmet medical need. Veru's pipeline also includes other treatments for breast cancer and COVID-19, indicating a robust commitment to oncology and sexual health management.
Veru Inc. has initiated its Phase 3 VERACITY clinical trial for sabizabulin, an innovative oral treatment for metastatic castration-resistant prostate cancer. This trial aims to evaluate sabizabulin's efficacy and safety against other androgen receptor-targeting agents. The study will enroll 245 patients across 45 sites in the U.S. Preliminary results from previous trials indicated sabizabulin was well-tolerated and demonstrated significant tumor efficacy. The primary endpoint is median radiographic progression-free survival, indicating sabizabulin's potential to address unmet medical needs in advanced prostate cancer treatment.
Veru Inc. (NASDAQ: VERU) has initiated a Phase 2 clinical trial for VERU-100, a new GnRH antagonist for treating hormone-sensitive advanced prostate cancer. The trial aims to assess the drug's efficacy and safety in 35 participants, with results expected by the second half of 2021. Current androgen deprivation therapies face limitations as no long-acting formulations exist. If successful, VERU-100 could fill an unmet need in prostate cancer care, potentially capturing a share of the $2.8 billion ADT market.
Veru Inc. (NASDAQ: VERU) reported significant findings from its Phase 2 study of enobosarm, an oral selective androgen receptor agonist, demonstrating strong antitumor effects in AR+ER+HER2- metastatic breast cancer patients with ≥ 40% AR expression. The study included 136 heavily pretreated subjects, and results indicated a 48% tumor response rate in those with ≥ 40% AR positivity. Enobosarm was well tolerated and shows potential as a new endocrine therapy. A Phase 3 ARTEST study is set to initiate in Q3 2021 to further assess enobosarm's efficacy.
Veru Inc. has reported promising results for sabizabulin in ongoing Phase 1b/2 clinical trials, showcasing its safety and efficacy in treating men with metastatic castration resistant prostate cancer. The study revealed a 20.7% overall response rate and a median progression-free survival of 10.8 months for some patients. A Phase 3 trial, named VERACITY, is set to commence this month, targeting a key market need. Dr. Mitchell Steiner emphasized potential broad use of sabizabulin prior to chemotherapy, marking an important step in prostate cancer treatment.
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 8:00 a.m. ET. They focus on developing treatments for prostate and breast cancer, including sabizabulin and enobosarm. A Phase 3 clinical trial for sabizabulin targeting metastatic castration-resistant prostate cancer will start early June. The company’s product pipeline includes ongoing studies for enobosarm in breast cancer and other candidates. The presentation will be accessible for 90 days on their website.